title: Effect of formaldehyde inactivation on poliovirus.
abstract: Inactivated polio vaccines, which have been used in many countries for more than 50 years, are produced by treating live poliovirus (PV) with formaldehyde. However, the molecular mechanisms underlying virus inactivation are not well understood. Infection by PV is initiated by virus binding to specific cell receptors, which results in viral particles undergoing sequential conformational changes that generate altered structural forms (135S and 80S particles) and leads to virus cell entry. We have analyzed the ability of inactivated PV to bind to the human poliovirus receptor (hPVR) using various techniques such as ultracentrifugation, fluorescence-activated cell sorting flow cytometry and real-time reverse transcription-PCR (RT-PCR). The results showed that although retaining the ability to bind to hPVR, inactivated PV bound less efficiently in comparison to live PV. We also found that inactivated PV showed resistance to structural conversion in vitro, as judged by measuring changes in antigenicity, the ability to bind to hPVR, and viral RNA release at high temperature. Furthermore, viral RNA from inactivated PV was shown to be modified, since cDNA yields obtained by RT-PCR amplification were severely reduced and no infectious virus was recovered after RNA transfection into susceptible cells. Importance: This study represents a novel insight into the molecular mechanisms responsible for poliovirus inactivation. We show that inactivation with formaldehyde has an effect on early steps of viral replication as it reduces the ability of PV to bind to hPVR, decreases the sensitivity of PV to convert to 135S particles, and abolishes the infectivity of its viral RNA. These changes are likely responsible for the loss of infectivity shown by PV following inactivation. Techniques used in this study represent new approaches for the characterization of inactivated PV products and could be useful in developing improved methods for the production and quality control testing of inactivated polio vaccines. Measuring the antigenicity, capsid stability, and RNA integrity of inactivated PV samples could help establishing the optimal balance between the loss of infectivity and the preservation of virus antigenicity during inactivation.
authors.affiliation: Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom thomas.wilton@nibsc.org.
authors.forename: Thomas
authors.initials: T
authors.lastname: Wilton
authors.affiliation: Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom.
authors.forename: Glynis
authors.initials: G
authors.lastname: Dunn
authors.affiliation: Division of Biotherapeutics, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom.
authors.forename: David
authors.initials: D
authors.lastname: Eastwood
authors.affiliation: Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom.
authors.forename: Philip D
authors.initials: PD
authors.lastname: Minor
authors.affiliation: Division of Virology, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, United Kingdom.
authors.forename: Javier
authors.initials: J
authors.lastname: Martin
mesh_terms: D002460:Cell Line; D005434:Flow Cytometry; D005557:Formaldehyde / Q000494:pharmacology*; D006801:Humans; D017955:Poliovirus / Q000187:drug effects* / Q000235:genetics; D012367:RNA, Viral / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D011991:Receptors, Virus / Q000187:drug effects; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D012367:RNA, Viral; D011991:Receptors, Virus; D005557:Formaldehyde
references.citation: J Virol Methods. 1991 Aug;33(3):367-74
references.pmid: 1723736
references.citation: J Hyg (Lond). 1962 Mar;60:113-21
references.pmid: 13866112
references.citation: Asian Pac J Cancer Prev. 2007 Jan-Mar;8(1):55-9
references.pmid: 17477772
references.citation: Vaccine. 2004 Dec 9;23(4):511-7
references.pmid: 15530700
references.citation: Am J Public Health Nations Health. 1954 May;44(5):563-70
references.pmid: 13148396
references.citation: J Virol. 1995 Aug;69(8):4823-9
references.pmid: 7609049
references.citation: J Biol Stand. 1989 Apr;17(2):137-50
references.pmid: 2541133
references.citation: J Virol. 1988 May;62(5):1781-94
references.pmid: 2451757
references.citation: Pharmeuropa Bio. 2003 Jul;2003(1):23-50
references.pmid: 14563307
references.citation: Virology. 1962 Oct;18:212-23
references.pmid: 13962933
references.citation: J Virol Methods. 2007 Oct;145(1):14-21
references.pmid: 17561276
references.citation: Methods Mol Biol. 2000;132:365-86
references.pmid: 10547847
references.citation: Curr Opin Virol. 2013 Jun;3(3):309-15
references.pmid: 23759252
references.citation: Avian Dis. 1991 Jul-Sep;35(3):505-14
references.pmid: 1835374
references.citation: J Virol. 1990 May;64(5):1934-45
references.pmid: 2157861
references.citation: Biologicals. 2005 Mar;33(1):29-39
references.pmid: 15713554
references.citation: EMBO J. 1989 May;8(5):1567-79
references.pmid: 2548847
references.citation: Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):79-84
references.pmid: 10618374
references.citation: Nucleic Acids Res. 1999 Nov 15;27(22):4436-43
references.pmid: 10536153
references.citation: EMBO J. 1994 Dec 15;13(24):5855-62
references.pmid: 7813425
references.citation: Nat Rev Microbiol. 2007 Dec;5(12):952-8
references.pmid: 17965726
references.citation: Bull World Health Organ. 2004 Jan;82(1):47-52
references.pmid: 15106300
references.citation: Virol J. 2009 Dec 07;6:217
references.pmid: 19968865
references.citation: Curr Top Microbiol Immunol. 2010;343:43-89
references.pmid: 20397067
references.citation: Lancet. 2008 Apr 19;371(9621):1385-7
references.pmid: 18424327
references.citation: N Engl J Med. 2014 Feb 27;370(9):818-28
references.pmid: 24571754
references.citation: J Gen Virol. 1993 Apr;74 ( Pt 4):685-90
references.pmid: 7682250
references.citation: J Virol. 1997 Dec;71(12):9770-7
references.pmid: 9371643
references.citation: Vaccine. 1989 Dec;7(6):513-20
references.pmid: 2481909
references.citation: J Gen Virol. 2003 Jul;84(Pt 7):1781-1788
references.pmid: 12810872
references.citation: J Gen Virol. 2010 Jun;91(Pt 6):1450-60
references.pmid: 20147516
references.citation: J Mol Recognit. 1998 Winter;11(1-6):2-9
references.pmid: 10076797
references.citation: Structure. 1997 Jul 15;5(7):961-78
references.pmid: 9261087
references.citation: J Virol. 2006 Oct;80(19):9687-96
references.pmid: 16973573
references.citation: Vaccine. 1991 Jun;9(6):398-402
references.pmid: 1887669
references.citation: EMBO J. 2000 Mar 15;19(6):1207-16
references.pmid: 10716921
references.citation: Annu Rev Microbiol. 2002;56:677-702
references.pmid: 12142481
references.citation: J Gen Virol. 1971 Jun;11(3):147-56
references.pmid: 4105288
references.citation: J Gen Virol. 2012 Mar;93(Pt 3):457-474
references.pmid: 22128250
references.citation: Virology. 1991 Apr;181(2):451-8
references.pmid: 1707566
references.citation: Science. 1985 Sep 27;229(4720):1358-65
references.pmid: 2994218
references.citation: Am J Epidemiol. 2013 Nov 15;178(10):1579-87
references.pmid: 24100955
references.citation: Vaccine. 2007 Oct 10;25(41):7041-6
references.pmid: 17825459
references.citation: J Immunol. 2013 Jul 15;191(2):884-91
references.pmid: 23772035
references.citation: Biologicals. 1997 Sep;25(3):299-306
references.pmid: 9324998
references.citation: Vaccine. 2011 Dec 6;29(52):9655-62
references.pmid: 22027488
references.citation: Risk Anal. 2006 Dec;26(6):1533-40
references.pmid: 17184395
references.citation: J Virol. 2011 Jan;85(2):776-83
references.pmid: 20980499
references.citation: J Virol. 2006 Jan;80(1):172-80
references.pmid: 16352541
references.citation: Am J Public Health. 2008 Jul;98(7):1322-30
references.pmid: 18511720
references.citation: Cell. 1989 Mar 10;56(5):855-65
references.pmid: 2538245
references.citation: Vaccine. 1995 Nov;13(16):1603-10
references.pmid: 8578849
references.citation: Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):73-8
references.pmid: 10618373
references.citation: Virology. 1961 Apr;13:439-47
references.pmid: 13790415
references.citation: Virus Res. 1999 Aug;62(2):185-92
references.pmid: 10507328
references.citation: J Virol. 1996 Oct;70(10):7125-31
references.pmid: 8794359
references.citation: Vaccine. 2009 May 5;27(20):2649-52
references.pmid: 19428874
references.citation: J Virol. 2010 May;84(9):4426-41
references.pmid: 20181687